Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q3 2020 Earnings Presentation
19 slides from Q-linea Ab's earnings presentation, Nov 5, 2020
Slide 1: Presentation Q3(20)
Presentation Q3(20) Jonas Jarvius, CEO Anders Lundin, CFO STRICTLY PRIVATE AND CONFIDENTIAL
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea 3rd quarter
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 3rd quarter Lead product ASTar® Q-linea is developing disruptive solutions for faster infectious disease diagnostics, first product Introduction to the company targeting sepsis Major steps towards start of clinical study
Slide 4: Sepsis – a global health crisis
Sepsis – a global health crisis 4
Slide 5: ASTar workflow vs current workflow
Up to 40 hours faster actionable results DAY 1 DAY 2 DAY 3 DAY 4 Plates are streaked CURRENT WORKFLOW Gram Susceptibility Patient to perform a Colony blood draw stain clean culture selection Determination (AST) Optimized Time to Blood bottle Rapid ID Overnight 0.5 McFarland therapy Actionable incuba
Slide 6: ASTar – a platform designed to save lifetimes
ASTar – a platform designed to save lifetimes Easy to use Comprehensive • Fully automated • Large antibiotic panel • <1 min hands-on time • Long concentration • Load-and go workflow ranges • Fastidious and non- fastidious bacteria Fast • Support additional • Results in 3 to 6 hours samples (e.g. uri
Slide 7: Value of true MIC
Value of true MIC Optimization of antimicrobial use through MIC and drug dosing 7
Slide 8: Excellent reproducibility
Excellent reproducibility From blood culture bottles E.coli – Pip/Tazo E.coli – Ceftazidime S.Aureus– Gentamicin 4x Reported MIC 2x 1x ASTar analysis 0.5x 0.25x 10 different positive blood culture flasks from different donors spiked with same bacterial isolate From isolates 4x Reported MIC 2x 1x Sem
Slide 9: Key highlights third quarter
Key highlights third quarter Positive feedback from users of ASTar & benefits of rapid AST Uppsala University Hospital has been testing ASTar during autumn with excellent results. 17 patients sampled and analyzed with an antibiotic panel consisted of 29 antimicrobials for both fastidious and non-fas
Slide 10: Potential benefits of ASTar for septic patients
Potential benefits of ASTar for septic patients ASTar was much faster than standard AST method and provided a broader answer One example for Uppsala University Hospital pre-clinical study Man 73 years from neuro surgery intermediate care ward, diagnosed with aspiration pneumonia ASTar reported ASTar
Slide 11: Key highlights third quarter
Key highlights third quarter Most of the analytical study completed An integral part of the claims for CE approval We have finalized blood bottle types to be included in 1st CE release 8 different blood culture bottles (Aerobic, Anaerobic, Lytic) The most common used in EU and USA Close to 100% perf
Slide 12: Key highlights third quarter
Key highlights third quarter Most of the analytical study completed An integral part of the claims for CE approval Stability of production batches for consumables extends 4 months Goal is to have at least 6-month stability at launch Prior data has indicated >12 month stability for consumables Looks
Slide 13: Key highlights third quarter
Key highlights third quarter First commercial instruments delivered to Q-linea Instrument We have received the first production batch of instruments (0-series) No changes for the instrument planned for commercial launch Consumables & production Formal validation is currently ongoing with good result
Slide 14: The effects of the Corona pandemic on Q-linea
The effects of the Corona pandemic on Q-linea So far, the effects have not caused a delay on Q-linea operations Most activities coupled to ASTar launch are still internal. The adoption of new work routines have had minimal impact on the project during the third quarter. We have seen a slight effect
Slide 15: Income statement third quarter
Income statement third quarter Net sales in the third quarter amounted to SEK 0 million (0). Operating result totalled SEK -50.0 million (-35.8). The company reported a loss after tax of SEK -48.7 million (-35.1). Earnings per share, before and after dilution amounted to SEK -1.80 (-1.53). Figures i
Slide 16: Balance sheet at end of third quarter
Balance sheet at end of third quarter Cash and cash equivalents amounted to SEK 17.8 million (26.0) Short-term investments in fixed-income funds SEK 205,5 million (150,4) and the current portion of non-current assets (listed bonds) SEK 151.4 million (30.1). Non-current assets, listed bonds SEK 34.5
Slide 17: Cash flow statement third quarter
Cash flow statement third quarter Cash flow from operating activities SEK -46.7 million (-35.8). Increased cash outflow from operating activities mainly due to a larger operating loss. Cash flow from investing activities SEK 27.2 million (35.8). Short term interest funds were sold during the third q
Slide 18: Equal and better care for everyone
Sign up for our upcoming webinar on November 10 “Equal and better • ASTar – designed to save lifetimes care • Sneak peek on an for everyone” upcoming exciting product • Q&A 18
Slide 19: Thank you
Thank you O-LINEA™* 19